T-cell therapy for chemotherapy-refractory CMV infection.

被引：0
|
作者：
Einsele, H
Rufer, N
Roosnek, E
Hebart, H
Loeffler, J
Grigoleit, U
Kleihauer, A
Bruemmendorf, T
Riegler, S
Jahn, G
Sinzger, C
Kanz, L
机构：
[1] Univ Tubingen Hosp, Tubingen, Germany
[2] Univ Geneva, Hop Cantonal, CH-1211 Geneva, Switzerland
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2058
引用
收藏
页码：478A / 478A
页数：1
相关论文
共 50 条
  • [1] T-cell therapy for chemotherapy-refractory CMV infection.
    Einsele, H
    Rufer, N
    Roosneck, E
    Hebart, H
    Grigoleit, U
    Jahn, G
    Szinzger, C
    LEUKEMIA, 2002, 16 (03) : 408 - 408
  • [2] T-cell responses during early therapy for HCV infection.
    Lauer, GM
    Lucas, M
    Ouchi, K
    Kim, AY
    Day, CL
    Casson, DR
    Sheridan, I
    Lavender, B
    Ghandhi, RT
    Reiser, M
    Chung, RT
    Walker, BD
    Klenerman, P
    HEPATOLOGY, 2003, 38 (04) : 354A - 355A
  • [3] CMV-specific T-cell immunity in solid organ transplant recipients at low risk of CMV infection. Chronology and applicability in preemptive therapy
    Mena-Romo, Juan Damian
    Romero, Pilar Perez
    Martin-Gandul, Cecilia
    Gentil, Miguel Angel
    Suarez-Artacho, Gonzalo
    Lage, Ernesto
    Sanchez, Magdalena
    Cordero, Elisa
    JOURNAL OF INFECTION, 2017, 75 (04) : 336 - 345
  • [4] Adoptive T-cell therapy for CMV
    Barrett, J
    CYTOTHERAPY, 2002, 4 (01) : 1 - 1
  • [5] Successful Treatment of Chemotherapy-Refractory Angioimmunoblastic T Cell Lymphoma with Cyclosporin A
    Kobayashi, Tsutomu
    Kuroda, Junya
    Uchiyama, Hitoji
    Matsumoto, Yosuke
    Horiike, Shigeo
    Taniwaki, Masafumi
    ACTA HAEMATOLOGICA, 2012, 127 (01) : 10 - 15
  • [6] Allogeneic bone marrow transplantation for chemotherapy-refractory hepatosplenic γδ T-cell lymphoma -: Case report and review of the literature
    Domm, JA
    Thompson, MA
    Kutteseh, JF
    Acra, S
    Frangoul, H
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2005, 27 (11) : 607 - 610
  • [7] Next Generation T-Cell Therapy for CMV Infection Post Allogeneic SCT
    Shafat, Manar S.
    Dias, Juliana
    Palton, Morgan
    Lowdell, Mark
    Pule, Martin
    Peggs, Karl S.
    Roddie, Claire
    MOLECULAR THERAPY, 2019, 27 (04) : 458 - 458
  • [8] A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas
    Enblad, G
    Hagberg, H
    Erlanson, M
    Lundin, J
    MacDonald, AP
    Repp, R
    Schetelig, J
    Seipelt, G
    Österborg, A
    BLOOD, 2004, 103 (08) : 2920 - 2924
  • [9] T cell therapy of CMV and HIV infection
    Greenberg, PD
    Lewinsohn, D
    Gilbert, MJ
    Lonergan, M
    Lisziewicz, J
    Brodie, S
    Corey, L
    Reynolds, T
    Riddell, SR
    HEMATOLOGY AND CELL THERAPY, 1998, 40 (02): : 96 - 96
  • [10] T-CELL IMMUNITY AND CMV INFECTION IN HEMOPHILIAC PATIENTS
    WEINTRUB, PS
    AMMANN, AJ
    ABRAMS, DI
    COWAN, MJ
    DREW, WL
    KOERPER, MA
    ADDIEGO, JE
    CLINICAL RESEARCH, 1983, 31 (01): : A120 - A120
12345